Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens
Emma T. Crooks(San Diego Biomedical Research Institute), James Μ. Binley(San Diego Biomedical Research Institute), Laurent Verkoczy(Duke University), John P. Nolan(Scintillon Institute), Bette Korber(Los Alamos National Laboratory), Keiko Osawa(San Diego Biomedical Research Institute), Max Crispin(University of Southampton), Alessio D’Addabbo(University of Southampton), Yaroslav Tsybovsky(Frederick National Laboratory for Cancer Research), Evan M. Cale(National Institute of Allergy and Infectious Diseases), Joel D. Allen(University of Southampton), Francisco Almanza(San Diego Biomedical Research Institute), Kshitij Wagh(Los Alamos National Laboratory), Huihui Mou(Broad Institute), Jinsong Zhang(Nanjing Forestry University), Alyssa Thomas(San Diego Biomedical Research Institute), E. Duggan(Scintillon Institute)
Cited by 19
Related Papers
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
|Cell|2020|4.5k
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
|Nature|2013|2.1k
Site-specific glycan analysis of the SARS-CoV-2 spike
|Science|2020|1.7k
Evolutionary and immunological implications of contemporary HIV-1 variation
|British Medical Bulletin|2001|533
MIFlowCyt‐EV: a framework for standardized reporting of extracellular vesicle flow cytometry experiments
|Journal of Extracellular Vesicles|2020|514